Blair William & Co. IL Acquires New Stake in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Blair William & Co. IL purchased a new stake in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 323,900 shares of the company's stock, valued at approximately $551,000. Blair William & Co. IL owned about 0.79% of Vigil Neuroscience at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of VIGL. Walleye Capital LLC lifted its stake in Vigil Neuroscience by 334.4% during the third quarter. Walleye Capital LLC now owns 119,792 shares of the company's stock worth $407,000 after purchasing an additional 92,217 shares during the last quarter. Verition Fund Management LLC purchased a new stake in Vigil Neuroscience during the third quarter valued at about $442,000. Point72 Asset Management L.P. boosted its holdings in Vigil Neuroscience by 7.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company's stock valued at $5,440,000 after acquiring an additional 115,000 shares during the period. Geode Capital Management LLC raised its holdings in Vigil Neuroscience by 41.9% during the 3rd quarter. Geode Capital Management LLC now owns 226,083 shares of the company's stock valued at $769,000 after buying an additional 66,712 shares during the last quarter. Finally, abrdn plc raised its stake in shares of Vigil Neuroscience by 124.9% during the fourth quarter. abrdn plc now owns 528,472 shares of the company's stock valued at $898,000 after acquiring an additional 293,461 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company's stock.

Vigil Neuroscience Stock Up 6.4 %

Shares of NASDAQ VIGL traded up $0.09 during midday trading on Wednesday, hitting $1.49. The stock had a trading volume of 84,014 shares, compared to its average volume of 471,403. The company has a market cap of $73.19 million, a P/E ratio of -0.72 and a beta of 1.94. The business's 50 day moving average is $2.22 and its 200-day moving average is $2.54. Vigil Neuroscience, Inc. has a 52 week low of $1.31 and a 52 week high of $6.06.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last issued its earnings results on Thursday, March 13th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.08). As a group, analysts expect that Vigil Neuroscience, Inc. will post -2.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on VIGL. Wedbush cut their target price on shares of Vigil Neuroscience from $24.00 to $13.00 and set an "outperform" rating on the stock in a research note on Friday, March 14th. Guggenheim reaffirmed a "buy" rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. Finally, HC Wainwright cut their price target on Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating on the stock in a research note on Friday, March 14th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $16.25.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.